Modelling and analysis of glucocorticoid action in acute lymphoblastic leukemia

Glucocorticoids (GCs) induce apoptosis in leukocytes and remain a cornerstone of acute lymphoblastic leukemia (ALL) therapy, though resistance and toxicity remain problems. GEB052, a previously published Boolean model of the glucocorticoid receptor (GR) and its connected proteins, input (GC) and outputs (cell death and inflammation), generated insight into glucocorticoid resistance. The present study improved the model's predictive capacity through the inclusion of 26 microRNAs (miRs), resulting in a new model: GAO078 (78 nodes, 274 edges). GAO078 demonstrated improved correct prediction rates compared with GEB052, while dependency matrix and DRUGSURV analyses, together with laboratory validation, identified signal transducer and activator of transcription 5B (STAT5B) as an important level of control linked to GCs and apoptosis. The tyrosine kinase inhibitor dasatinib (DAS), which targets STAT5B and conventionally targets break point cluster (BCR)‑Abelson tyrosine kinase gene (ABL), was shown in ALL cell lines to have selective efficacy for GC‑resistant cells. Notably, cytotoxicity was demonstrated for BCR‑ABL‑negative leukemic cells, suggesting the potential for the use of DAS in this type of leukemia cells, upon further testing. GAO078 model analysis also identified miR‑27a, miR‑20a and miR‑9 to feature frequently and have clinical significance. Laboratory analysis of dexamethasone/DAS‑treated ALL cells showed an increase in the expression of these miRs. All three miRs are predicted to target nuclear receptor coactivators and corepressors; therefore, the outcome on nuclear receptor action could be a balance between multiple, complex networks. The findings of the present study demonstrate the significance of GR signaling and microRNA crosstalk in the determination of cell fate and emphasize the value of a systems biology approach in helping to identify routes towards reducing GC resistance and potentially improving future leukemia treatment.

Authors

Institutions

Publication Details

Journal
International Journal of Oncology
Published
2026-11-18
DOI
https://doi.org/10.3892/ijo.2026.5963
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modelling and analysis of glucocorticoid action in acute lymphoblastic leukemia

Delta Patricia Menendez Creamer, Marija Krstic–Demonacos, Emyr Yosef Bakker, Athar Aziz et al.
International Journal of Oncology
Acute Lymphoblastic Leukemia research
article

Modelling and analysis of glucocorticoid action in acute lymphoblastic leukemia

Delta Patricia Menendez Creamer, Marija Krstic–Demonacos, Emyr Yosef Bakker, Athar Aziz, Hend Alrasheedi, Aïsha Othman, Costas Demonacos, Alireza Fatahian, Muhammad-Nurudeen Nurudeen
article en

Abstract

Glucocorticoids (GCs) induce apoptosis in leukocytes and remain a cornerstone of acute lymphoblastic leukemia (ALL) therapy, though resistance and toxicity remain problems. GEB052, a previously published Boolean model of the glucocorticoid receptor (GR) and its connected proteins, input (GC) and outputs (cell death and inflammation), generated insight into glucocorticoid resistance. The present study improved the model's predictive capacity through the inclusion of 26 microRNAs (miRs), resulting in a new model: GAO078 (78 nodes, 274 edges). GAO078 demonstrated improved correct prediction rates compared with GEB052, while dependency matrix and DRUGSURV analyses, together with laboratory validation, identified signal transducer and activator of transcription 5B (STAT5B) as an important level of control linked to GCs and apoptosis. The tyrosine kinase inhibitor dasatinib (DAS), which targets STAT5B and conventionally targets break point cluster (BCR)‑Abelson tyrosine kinase gene (ABL), was shown in ALL cell lines to have selective efficacy for GC‑resistant cells. Notably, cytotoxicity was demonstrated for BCR‑ABL‑negative leukemic cells, suggesting the potential for the use of DAS in this type of leukemia cells, upon further testing. GAO078 model analysis also identified miR‑27a, miR‑20a and miR‑9 to feature frequently and have clinical significance. Laboratory analysis of dexamethasone/DAS‑treated ALL cells showed an increase in the expression of these miRs. All three miRs are predicted to target nuclear receptor coactivators and corepressors; therefore, the outcome on nuclear receptor action could be a balance between multiple, complex networks. The findings of the present study demonstrate the significance of GR signaling and microRNA crosstalk in the determination of cell fate and emphasize the value of a systems biology approach in helping to identify routes towards reducing GC resistance and potentially improving future leukemia treatment.

International Journal of OncologyVol. 69(6)
University of Lancashire (GB), University of Manchester (GB), University of Salford (GB)
Good health and well-being
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon